Pertuzumab (Perjeta) — targeted therapy for breast cancer with HER2 overexpression

What is pertuzumab (Perjeta) in simple words

Pertuzumab (Perjeta) — a targeted drug for breast cancer where tumour cells carry too much of a specific growth-driving receptor.

It belongs to the same drug class as trastuzumab — both attach to the same receptor, but at different binding sites. That is the key point. Blocking two different sites on the same receptor at the same time disrupts the growth signal more completely than either drug alone can achieve.

Pertuzumab is never given by itself. It works as part of a pair with trastuzumab. Together they address two separate mechanisms through which the receptor pushes the tumour to grow. This dual approach became a standard component of treatment after clinical data showed it improved outcomes.

Which patients need both drugs, at what stage and in what combination — those answers depend on individual assessment. Not every patient with this cancer type needs this drug.

How pertuzumab works

The growth receptor it targets sits on the surface of tumour cells. In cancers where this receptor is overexpressed, it sends continuous signals driving cell division. Trastuzumab blocks one part of this receptor. Pertuzumab blocks a different part — specifically the section through which the receptor connects with other nearby receptors to amplify the growth signal.

When both parts are blocked simultaneously, the growth signal is suppressed more completely than with either drug alone. The tumour loses two different mechanisms it was using to sustain itself.

Clinical data showed that adding pertuzumab to trastuzumab-based treatment improved outcomes in advanced disease and in early-stage disease when given before surgery. That is the rationale for the combination.

What conditions pertuzumab is used for

Pertuzumab is used exclusively in breast cancer where the HER2 growth receptor is overexpressed:

• advanced or metastatic breast cancer — as part of first-line treatment;

• early breast cancer — given before surgery to shrink the tumour;

• early breast cancer — given after surgery in patients with residual disease or high recurrence risk.

In advanced disease, adding pertuzumab to a regimen that already included trastuzumab and cytotoxic treatment produced a meaningful survival improvement. For a setting where prognosis had been difficult, that improvement mattered — and it shifted what became the accepted standard approach.

In early breast cancer given before surgery, the combination produced higher rates of complete tumour elimination at the time of the operation. Whether that translates into long-term benefit differs by patient — but in high-risk cases, it is a clinically meaningful goal.

When pertuzumab may be especially relevant

It tends to come up when:

• breast cancer has spread and requires first-line systemic treatment targeting this receptor;

• early breast cancer carries a high risk of recurrence and treatment before surgery is planned;

• surgery has already taken place but the tumour was not completely eliminated by pre-surgical treatment;

• the treating oncologist is considering dual targeted therapy rather than a single targeted drug.

The pre-surgical setting is where I have seen the most variation in how this combination is used. Not every patient with this type of early breast cancer needs both targeted drugs before surgery. The decision depends on tumour size, lymph node involvement, and how aggressive the cancer appears to be. More intensive treatment upfront is not always appropriate — it depends on the individual risk profile.

After surgery, the decision about whether to add pertuzumab to post-surgical treatment is also individualised. It is not automatic.

What needs to be checked before starting treatment

Before pertuzumab is considered, the oncologist will typically assess:

• confirmed overexpression of the growth receptor — by tissue testing;

• cancer stage and extent of disease;

• heart function — echocardiogram before starting;

• prior treatment history;

• hormone receptor status — relevant for the overall treatment plan;

• kidney and liver function;

• performance status.

Heart function is the assessment I focus on most carefully. Both pertuzumab and trastuzumab can affect the heart’s pumping efficiency — and they are almost always given together, which means the cardiac monitoring requirements apply to both simultaneously. The baseline echocardiogram establishes a reference point. If pumping function drops during treatment, the decision about whether to continue, pause or stop is made against that baseline. Without it, there is no meaningful comparison.

How treatment is carried out

Pertuzumab is given intravenously every three weeks — on the same schedule as trastuzumab, so both are administered at the same visit. Chemotherapy is added for an initial phase in most protocols.

In advanced disease, pertuzumab and trastuzumab continue as long as treatment is working. In early breast cancer before surgery, a defined number of cycles is given. After surgery, post-treatment duration varies by protocol.

Monitoring during treatment:

• heart function every three months — echocardiogram;

• blood count and chemistry at each cycle;

• imaging to assess response in advanced disease;

• monitoring for infusion reactions at each visit;

• diarrhoea tracking — a specific side effect to watch with pertuzumab.

Diarrhoea is more common with pertuzumab than with trastuzumab alone. For most patients it is manageable. For some it is significant enough to require dose delay or adjustment. I always ask about it specifically at every visit — not as part of a general side effect review, but because it is one of the most common reasons treatment gets interrupted when it does not need to be.

Possible side effects

Side effects that may appear:

• diarrhoea — more frequent than with trastuzumab alone;

• nausea;

• fatigue;

• reduced heart pumping function;

• hair loss — when given alongside chemotherapy;

• skin rash;

• infusion reactions — chills, fever, usually with earlier infusions;

• reduced white blood cell counts — when given with chemotherapy;

• joint and muscle pain;

• mouth sores.

The diarrhoea point deserves specific attention. It can start early in treatment and be persistent. It is usually manageable with diet adjustments and medication — but the patient needs to know to report it rather than managing it independently at home. Diarrhoea that is not addressed can affect nutrition, electrolyte balance and quality of life in ways that accumulate over a long treatment course.

When to contact a doctor urgently

Contact your doctor without delay if any of the following develop:

• breathlessness at rest or with minimal activity;

• ankle or leg swelling;

• feeling of the heart racing or beating irregularly;

• chest pain;

• diarrhoea that is severe or not responding to home management;

• chills or fever during an infusion;

• significant mouth sores preventing adequate eating;

• sudden significant deterioration.

Breathlessness and swelling together, in a patient on both targeted drugs, means cardiac assessment that day. Not at the next scheduled visit.

Why pertuzumab is not right for everyone

What affects whether this drug is part of the treatment plan:

• growth receptor not overexpressed — pertuzumab has no relevant target;

• heart function already reduced at baseline;

• prior cardiac damage from other treatments;

• early breast cancer where dual targeted therapy has not been established as necessary based on the risk profile;

• advanced disease where prior treatment has already included this drug.

Not every patient with this type of breast cancer needs both targeted drugs. Sometimes trastuzumab alone is appropriate — lower toxicity, still meaningful benefit, supported by substantial evidence. Adding pertuzumab increases the treatment intensity. That is justified when the evidence supports it and when the patient’s profile warrants it. Not as a default.

Can pertuzumab be combined with other treatments

It is always given with trastuzumab — the two are used as a pair. Chemotherapy is added for the initial treatment phase in most protocols. In hormone receptor-positive cancers, endocrine therapy is incorporated into the long-term plan.

The specific chemotherapy drugs used alongside the targeted pair vary by protocol and clinical setting. Each combination has its own evidence base and its own toxicity profile. The choice is not arbitrary.

What ‘no quick response’ means

In early breast cancer given before surgery, response is assessed at surgery — by examining the tissue that is removed. Complete elimination of tumour cells at that point is the goal. Some patients achieve it. Others have residual disease, which then informs what happens next.

In advanced disease, imaging assessments happen at defined intervals. Targeted drugs can produce slower visible changes than chemotherapy. Stability on early scans is not necessarily failure. I look at the trend across multiple time points rather than drawing conclusions from a single result.

Oncology consultation for pertuzumab (Perjeta) in Israel

At Tel Aviv Medical Clinic in Israel, consultations are available on pertuzumab and dual targeted treatment for breast cancer with HER2 overexpression. Israel is one of the countries where both pre-surgical and post-surgical pertuzumab-based regimens are actively used, and oncologists at the clinic follow ESMO and NCCN guidelines with experience across early and advanced disease settings. This includes decisions about whether dual targeted therapy is warranted, what post-surgical treatment should look like depending on pathological response, and how to manage cardiac monitoring throughout a long course of dual targeted treatment.

In Tel Aviv Medical Clinic, you can discuss:

• whether dual targeted therapy with pertuzumab is appropriate for your stage and risk profile;

• pre-surgical treatment planning in early breast cancer;

• post-surgical decisions based on how the tumour responded to treatment;

• cardiac monitoring requirements during dual targeted therapy;

• second opinion on a proposed treatment plan;

• treatment options in Israel and internationally.

Sometimes patients arrive having been offered both targeted drugs without a clear explanation of why two are needed rather than one. That question deserves a proper answer.

Frequently Asked Questions — Dr. Stefanskoy

1. If trastuzumab already targets this receptor, why is pertuzumab needed?

Because they attach to different parts of the same receptor. Trastuzumab blocks one binding site. Pertuzumab blocks a different one — the part through which the receptor connects with neighbouring receptors to amplify the growth signal. Blocking both disrupts two separate mechanisms through which the receptor drives tumour growth.

The clinical evidence supported this reasoning. In advanced breast cancer, adding pertuzumab to trastuzumab-based treatment improved survival outcomes. That was not assumed from the biology — it was demonstrated. The improvement was meaningful enough to change standard treatment.

2. Does everyone with this type of breast cancer need both targeted drugs?

No. In early-stage disease, the decision depends on tumour size, lymph node involvement and the overall risk of recurrence. Smaller tumours without lymph node involvement may be adequately treated with trastuzumab alone. Larger tumours, involved lymph nodes, or high-risk features shift the balance toward the combination.

In advanced disease, the combination is more consistently the standard. But even there, prior treatment history and what has already been tried affect the decision. This is not a question with a single answer across all patients.

3. Why is diarrhoea specifically a concern with pertuzumab?

It is one of the most common side effects — more frequent than with trastuzumab alone. The mechanism is not entirely clear, but it is consistent enough in clinical data that I always address it specifically before starting treatment.

For most patients it is manageable with dietary changes and medication. The risk is that patients manage it quietly at home without reporting it, and it gradually affects nutrition and quality of life over a long course of treatment. I ask about it at every visit. Early management is considerably easier than catching up with it after it has been going on for weeks.

4. How does the cardiac monitoring work with two targeted drugs?

Both pertuzumab and trastuzumab can reduce the heart’s pumping efficiency. When given together, the monitoring schedule is the same — echocardiogram every three months. The baseline reading before starting is essential, because all subsequent assessments are compared against it.

If pumping function drops significantly, treatment is paused until it recovers. In most cases it does. The key is catching the drop early — which is exactly what the scheduled monitoring is designed to do. Patients who understand why the echocardiograms are happening tend to take them more seriously and attend more reliably.

5. What does ‘complete response before surgery’ mean and why does it matter?

When treatment is given before surgery in early breast cancer, the surgeon removes the breast tissue and lymph nodes and examines them under a microscope. If no living cancer cells are found — that is a complete pathological response. The treatment eliminated all visible tumour.

This matters because it is associated with better long-term outcomes. It is not a guarantee — but patients who achieve it tend to do better over time than those with residual disease. When residual disease is found, the post-surgical treatment plan is adjusted accordingly. That is the other reason pre-surgical treatment is valuable — it provides information about how the cancer responds, which shapes what comes next.

6. Can pertuzumab be used after trastuzumab has stopped working?

If pertuzumab was not previously used alongside trastuzumab, it may be added at a later line. If both were already used together and the cancer progressed on that combination, adding pertuzumab back is generally not supported by evidence — the disease has already demonstrated resistance to the combination.

In that situation, other options in the same drug class exist — including drugs that use the receptor as a delivery mechanism for a chemotherapy payload. The approach shifts rather than repeating what has already failed.

7. What comes next if this combination stops working in advanced disease?

There are subsequent options in this drug class — including newer agents that target the same receptor through different mechanisms. The sequence of those options depends on what has already been used, what the receptor status looks like at the time of progression, and what the patient can tolerate.

Re-testing the receptor status at progression is sometimes appropriate. Tumours can change over time, and occasionally a result that was strongly positive at diagnosis has shifted. That information can be relevant for what comes next.

Important information

Pertuzumab (Perjeta) is considered only after confirmed growth receptor testing, cardiac function assessment, cancer staging and a full review of prior treatment history.

Do not start, stop or change treatment without consulting your treating physician.

For a consultation in Israel:

📞 +972-73-374-6844
📧 [email protected]
💬 WhatsApp: +972-52-337-3108